GOLGA6L7

Across TCGA pan-cancer cohorts, GOLGA6L7 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated GOLGA6L7 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher GOLGA6L7 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GOLGA6L7 expression acts as an unfavorable survival marker.

SARC, LUSC, and COAD are the cancer types where GOLGA6L7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	DFS	Median	All	0.101	0.632	.011	12	view →
LUSC	OS	Median	All	0.196	0.675	.044	6	view →
COAD	OS	Median	All	0.210	0.799	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

GOLGA6L7–SARC (DFS)

Open the SARC breakdown →